Between July 6 and 9, 2026, the Bénin’s Agence Béninoise du Médicament et des autres produits de Santé (ABMed) underwent a rigorous assessment by a team of World Health Organization (WHO) experts. This in-depth evaluation highlighted remarkable progress, positioning Bénin closer to achieving the prestigious WHO Maturity Level 3 certification—a global benchmark for pharmaceutical regulation.

Comprehensive WHO evaluation of Bénin’s health system

Over four days, the ABMed’s regulatory framework, operational procedures, and compliance mechanisms were meticulously reviewed by eight international WHO specialists. Every aspect was scrutinized, from drug licensing and market surveillance to pharmacovigilance and clinical trials, ensuring alignment with the strictest international standards.

The evaluation findings, presented in Cotonou on July 9, 2026, revealed significant advancements. The ABMed has demonstrated a strong commitment to strengthening the integrity of Bénin’s health supply chain, marking a critical milestone in the country’s pharmaceutical governance.

What does WHO Maturity Level 3 mean for Bénin?

The WHO Maturity Level 3 (ML3) represents a fully operational, stable, and integrated pharmaceutical regulatory system. Achieving this status means that Bénin’s national authority now has full control over the quality, safety, and efficacy of medicines circulating within its borders.

For the people of Bénin, this certification ensures access to reliable, high-quality healthcare products while combating the scourge of counterfeit drugs. Beyond public health benefits, the ML3 label enhances Bénin’s credibility on the global stage, fostering trust with international partners, promoting local pharmaceutical production, and facilitating cross-border trade.

Reforms since 2017 pave the way for WHO recognition

The latest WHO assessment was met with optimism by Bénin’s Health Minister, Professor Benjamin Hounkpatin, who emphasized the transformative impact of the country’s pharmaceutical reforms. Under his leadership, the government restructured the former pharmacy directorate into an autonomous agency (ABMed) and reinforced legal frameworks to create a robust regulatory environment.

In a public statement, the Minister praised the ABMed teams for their dedication, reaffirming the government’s unwavering support to secure this global certification.

Bénin poised to become a regional leader in pharmaceutical governance

If the final assessment confirms the transition to WHO Maturity Level 3, Bénin will join an elite group of Francophone nations in West Africa, trailing only Sénégal. This achievement would establish Bénin as a regional hub for pharmaceutical excellence, proving that strong political will and technical rigor can elevate national institutions to global standards.

A new chapter in Bénin’s public health history

The WHO’s July 2026 mission marks a historic turning point for Bénin’s health sector. While the preliminary results are promising, the ABMed must now implement the final recommendations to formalize its upgrade to ML3. This progress underscores a growing reality: patient safety and pharmaceutical sovereignty are no longer distant goals but tangible achievements within reach.